News and Announcements
Universal Biosenors Acquires Hemostasis Reference Laboratory
- Published December 19, 2016 12:57PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19th December 2016 – ASX Announcement
Universal Biosensors Inc (ASX: UBI) has announced that its wholly-owned Canadian operating subsidiary has signed an agreement with LifeLabs LP (LifeLabs) to acquire the assets of LifeLabs’ Hemostasis Reference Laboratory business (HRL) in preparation for future increased production requirements of Siemens’ Xprecia Stride™ test strips.
The HRL business has provided high-quality coagulation testing and calibration services to international customers for more than 20 years, including 5 years of services for UBI. HRL has one of the most diverse offerings of specialised coagulation services in the world.
To view the full announcement please click on the button below.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $16 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
